gut microbiota

The vaginal microbiome

Understanding the vaginal microbiome is essential not only for treating gynecological conditions but also for preventing them and promoting overall well-being.

Newly discovered microbiota-derived bile acids may help treat metabolic conditions

By suggesting that BA–MCYs can regulate the production of bile acids, the findings of a recent study offer insights for treating metabolic conditions such as diabetes.

The gut microbiome

A comprehensive look at the gut microbiome’s structure, functions, and strategies for sustaining its health.

Understanding the physiology of hunger: an exclusive interview with Alessio Fasano

The discussion with Professor Alessio Fasano highlights the complex interplay between homeostatic, hedonic, and microbiota-driven mechanisms in regulating hunger.

Bile acids promote the growth of bacteria associated with Crohn’s disease

High levels of bile acids drive bacterial colonization of the gut and exacerbate gut inflammation by altering the intestinal environment.

Largest study yet links coffee’s health benefits to gut microbes

The effects of coffee on health may be mediated by gut microbes such as L. asaccharolyticus and their metabolites.

From supplements to drug development: how Biogaia navigates both worlds

Nigel Titford, CEO at Biogaia Pharma, discusses the strategic considerations and challenges involved in working across both the dietary supplement and pharmaceutical sectors. 

A mother’s gut microbes may influence stem cells in the next generation

Mice born to mothers exposed to Akkermansia muciniphila during pregnancy showed improvements in stem cell activity.

Gut microbiota might be linked to brain development in preterm infants

A study revealed a link between gut microbiota composition and brain development in preterm infants, suggesting that specific bacteria and their metabolites can influence neurodevelopment.

The evolution of REBYOTA: milestones in microbiome-based therapeutics

On the second anniversary of its launch, Ferring Pharmaceuticals’ REBYOTA remains a landmark innovation in the prevention of recurrent Clostridioides difficile.

Subscribe to MicrobiomePost newsletter

Take full advantage of MicrobiomePost‘s features.

Scroll to Top